Compare BridgeBio Pharma Inc (BBIO) vs NICE Ltd (NICE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs NICE Ltd — how do they compare? BridgeBio Pharma Inc trades at $84.09 (market cap $16.27B), while NICE Ltd trades at $103 (market cap $5.87B). The key difference: BridgeBio Pharma Inc is far larger — about 2.8× NICE Ltd's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, NICE Ltd nearer its low. Which is the better fit depends on your goals.
| BBIO | NICE | |
|---|---|---|
Market Cap | $16.27B | $5.87B |
Sector | Health | Technology |
52-Week High | $90.17 | $170.37 |
52-Week Low | $44.81 | $83.15 |
Enterprise Value | $17.82B | $5.65B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About NICE Ltd
NICE Ltd. is a global leader in both enterprise software and cloud computing, specializing in customer experience and financial crime prevention solutions. The company's platform utilizes advanced analytics, AI, and automation to help organizations enhance customer interactions, ensure compliance, and combat fraud. NICE serves a diverse client base, including contact centers, financial institutions, and government agencies, by optimizing operations and improving service quality.
Read more on NICE →
